Literature DB >> 20020183

Casein kinase 2 inhibition differentially modulates apoptotic effect of trichostatin A against epithelial ovarian carcinoma cell lines.

Chung Soo Lee1, Eun-Ra Jang, Yun Jeong Kim, Soon Chul Myung, Wonyong Kim.   

Abstract

Histone deacetylase inhibitors and casein kinase 2 inhibitors have been shown to induce apoptosis. However, the combined effect of casein kinase 2 inhibition on the apoptotic effect of histone deacetylase inhibitor is unknown. We assessed the effect of casein kinase 2 inhibition on the apoptotic effect of trichostatin A in human epithelial carcinoma cell lines with respect to cell death signaling pathways. At concentrations that did not induce cell death, the casein kinase 2 inhibitor 4,5,6,7-tetrabromobenzotriazole inhibited activation of apoptotic proteins and changes in mitochondrial membrane permeability induced by the histone deacetylase inhibitor trichostatin A. These results suggest that casein kinase 2 inhibition may reduce trichostatin A-induced apoptosis in ovarian carcinoma cell lines by suppressing activation of apoptotic proteins and changes in mitochondrial membrane permeability, which both lead to caspase-3 activation. Casein kinase 2 inhibition, which does not induce a cytotoxic effect, may prevent histone deacetylase inhibitor-mediated apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20020183     DOI: 10.1007/s11010-009-0349-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  34 in total

1.  Neuroprotective effects of flavones on hydrogen peroxide-induced apoptosis in SH-SY5Y neuroblostoma cells.

Authors:  Sam Sik Kang; Ji Yeon Lee; Yoo Keum Choi; Gap Seok Kim; Byung Hee Han
Journal:  Bioorg Med Chem Lett       Date:  2004-05-03       Impact factor: 2.823

Review 2.  Mitochondria: a target for cancer therapy.

Authors:  Jeffrey S Armstrong
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

3.  Modulation of death receptor-mediated apoptosis by CK2.

Authors:  Guixia Wang; Kashif A Ahmad; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

4.  Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells.

Authors:  K Saravana Kumar; Jürgen Sonnemann; James F Beck
Journal:  Oncol Rep       Date:  2006-11       Impact factor: 3.906

Review 5.  Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.

Authors:  James S Duncan; David W Litchfield
Journal:  Biochim Biophys Acta       Date:  2007-08-30

Review 6.  Dissecting p53-dependent apoptosis.

Authors:  J E Chipuk; D R Green
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

Review 7.  Strategies for therapeutic targeting of the p53 pathway in cancer.

Authors:  K G Wiman
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

8.  Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell.

Authors:  C Nishioka; T Ikezoe; J Yang; H P Koeffler; A Yokoyama
Journal:  Leukemia       Date:  2008-01-10       Impact factor: 11.528

Review 9.  Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation.

Authors:  J E Allende; C C Allende
Journal:  FASEB J       Date:  1995-03       Impact factor: 5.191

10.  Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells.

Authors:  Jürgen Sonnemann; Isabel Hüls; Michael Sigler; Chithra D Palani; Le Thi Thu Hong; Uwe Völker; Heyo K Kroemer; James F Beck
Journal:  Oncol Rep       Date:  2008-07       Impact factor: 3.906

View more
  1 in total

1.  5,6-diiodo-1H-benzotriazole: new TBBt analogue that minutely affects mitochondrial activity.

Authors:  Daniel Paprocki; Maria Winiewska-Szajewska; Elżbieta Speina; Róża Kucharczyk; Jarosław Poznański
Journal:  Sci Rep       Date:  2021-12-08       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.